Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings is well-positioned in the growing market of radiopharmaceuticals, with a strong portfolio of products including Pylarify, Neuraceq, and DEFINITY. Management's conservative guidance for FY26 indicates a de-risked forecast horizon with likely upside, and the stock is not yet receiving credit for its promising Alzheimer's pipeline. With a number of potential catalysts in the near future, LNTH could see a return to double-digit revenue and earnings growth, and its attractive valuation makes it an attractive investment opportunity.

Lantheus Holdings is facing challenges with its FY26 GM guidance remaining intact, as they struggle with setting a realistic target. Their story is all about 2027 and 2026 is largely de-risked at this point, making it unnecessary to set a higher bar for the current fiscal year. The company's upcoming CEO transition and focus on giving the new leader an opportunity to make meaningful changes may also be amplifying uncertainty and concern about the company's performance. This is reflected in the company's declining revenue, with only a 52% year-over-year growth, driven by their strong Pharma Solutions portfolio and addition of Evergreen CDMO businesses, with their MK-6240 product representing half of their revenue in this category in the first quarter of FY25. As such, Lantheus Holdings may struggle to maintain its current financial performance and may face challenges in achieving its long-term goals.